Growth arrest in children undergoing renal transplantation is effective in the use of growth hormone therapy. However, the safety of growth hormone is controversial because of its potential immunomodulatory effect.
Recently, German scholar has studied the changes of helper T lymphocyte (TH) immunophenotype after treatment with rhGH in pediatric patients after renal transplantation. They were studied in 13 cases of children undergoing renal transplantation after treated with rhGH (Tx+GH group), 11 patients with chronic renal failure, the application of rhGH for the treatment of postoperative children (CRF+GH group) and children without rhGH treatment of 33 cases of renal transplantation (Tx group) as control group, cytokines, three groups were measured activation markers, stimulation and adhesion molecules, by flow cytometry, respectively measured in the application of rhGH before and after treatment for fourth, twelfth, eighteenth and 24 weeks of the project.
The results showed that there was no significant difference between Tx + GH group and Tx group before treatment. In the fourth week after the rhGH treatment, the interleukin -2 (IL-2) levels in the Tx+GH group were 3 times higher than those in the control group, while IL-4 and IL-13 increased by 70% at 12 weeks. The amounts of all three cytokines returned to baseline levels at 18th weeks. And did not find a rejection reaction. The baseline levels of all three cytokines in the CRF + GH group were higher than those after renal transplantation, but were not affected by rhGH therapy.
It is thought that rhGH treatment has a certain transient immune stimulating effect on children with stable kidney transplantation. Therefore, the immunosuppressive state and the function of the transplanted organs should be closely monitored in the use of rhGH.
Beijing In China